{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T16:57:50Z","timestamp":1777913870175,"version":"3.51.4"},"reference-count":165,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The diagnosis of a myeloid neoplasm relies on a combination of clinical, morphological, immunophenotypic and genetic features, and an integrated, multimodality approach is needed for precise classification. The basic diagnostics of myeloid neoplasms still rely on cell counts and morphology of peripheral blood and bone marrow aspirate, flow cytometry, cytogenetics and bone marrow trephine biopsy, but particularly in the setting of Ph\u2212 myeloproliferative neoplasms (MPN), the trephine biopsy has a crucial role. Nowadays, molecular studies are of great importance in confirming or refining a diagnosis and providing prognostic information. All myeloid neoplasms of chronic evolution included in this review, nowadays feature the presence or absence of specific genetic markers in their diagnostic criteria according to the current WHO classification, underlining the importance of molecular studies. Crucial differential diagnoses of Ph\u2212 MPN are the category of myeloid\/lymphoid neoplasms with eosinophilia and gene rearrangement of PDGFRA, PDGFRB or FGFR1, or with PCM1-JAK2, and myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN). This review focuses on morphological, immunophenotypical and molecular features of BCR-ABL1-negative MPN and their differential diagnoses. Furthermore, areas of difficulties and open questions in their classification are addressed, and the persistent role of morphology in the area of molecular medicine is discussed.<\/jats:p>","DOI":"10.3390\/cancers13143528","type":"journal-article","created":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T10:13:42Z","timestamp":1626257622000},"page":"3528","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics"],"prefix":"10.3390","volume":"13","author":[{"given":"Dominik","family":"Nann","sequence":"first","affiliation":[{"name":"Institute of Pathology and Neuropathology, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"},{"name":"Comprehensive Cancer Center, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falko","family":"Fend","sequence":"additional","affiliation":[{"name":"Institute of Pathology and Neuropathology, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"},{"name":"Comprehensive Cancer Center, University Hospital T\u00fcbingen, 72076 T\u00fcbingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"ref_1","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). Introduction and overview of the classification of myeloid neoplasms. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, revised, IARC Press. [4th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1136\/jcp.2010.080838","article-title":"Pitfalls in bone marrow pathology: Avoiding errors in bone marrow trephine biopsy diagnosis","volume":"64","author":"Wilkins","year":"2011","journal-title":"J. Clin. Pathol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/ijlh.12365","article-title":"ICSH guidelines for the standardization of bone marrow immunohistochemistry","volume":"37","author":"Torlakovic","year":"2015","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1751-553X.2008.01100.x","article-title":"ICSH guidelines for the standardization of bone marrow specimens and reports","volume":"30","author":"Lee","year":"2008","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1309\/AJCPNC99DHXIOOTD","article-title":"Aberrant myeloid maturation identified by flow cytometry in primary myelofibrosis","volume":"133","author":"Feng","year":"2010","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_6","first-page":"21215","article-title":"Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features","volume":"11","author":"Ouyang","year":"2014","journal-title":"Cytom. B Clin. Cytom."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? A systematic review and meta-analysis","volume":"89","author":"Titmarsh","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1055\/s-2006-939430","article-title":"Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia","volume":"32","author":"Johansson","year":"2006","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_10","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). Chronic myeloid leukaemia, BCR-ABL1-positive. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, IARC Press. [revised 4th ed.]."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia","volume":"306","author":"Bartram","year":"1983","journal-title":"Nature"},{"key":"ref_12","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). Chronic neutrophilic leukaemia. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, IARC Press. [revised 4th ed.]."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ajh.25688","article-title":"Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management","volume":"95","author":"Szuber","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/bjh.13600","article-title":"Chronic neutrophilic leukaemia and plasma cell-related neutrophilic leukaemoid reactions","volume":"171","author":"Bain","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1046\/j.1365-2141.1996.7082329.x","article-title":"Chronic neutrophil leukaemia in adolescence and young adulthood","volume":"94","author":"Hasle","year":"1996","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood.2019000611","article-title":"Genomic landscape of neutrophilic leukemias of ambiguous diagnosis","volume":"134","author":"Zhang","year":"2019","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-018-0058-7","article-title":"CSF3R-mutated chronic neutrophilic leukemia: Long-term outcome in 19 consecutive patients and risk model for survival","volume":"8","author":"Szuber","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"20834","DOI":"10.18632\/oncotarget.15355","article-title":"Clinical significance of CSF3R, SRSF2 and SETBP1 mutations in chronic neutrophilic leukemia and chronic myelomonocytic leukemia","volume":"8","author":"Ouyang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e244","DOI":"10.3324\/haematol.2014.113159","article-title":"Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia","volume":"99","author":"Meggendorfer","year":"2014","journal-title":"Haematologica"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s12094-017-1722-2","article-title":"Targeted next-generation sequencing identifies clinically relevant mutations in patients with chronic neutrophilic leukemia at diagnosis and blast crisis","volume":"20","author":"Langabeer","year":"2018","journal-title":"Clin. Transl. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ajh.24031","article-title":"ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia","volume":"90","author":"Elliott","year":"2015","journal-title":"Am. J. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13045-014-0077-1","article-title":"CSF3R, SETBP1 and CALR mutations in chronic neutrophilic leukemia","volume":"7","author":"Cui","year":"2014","journal-title":"J. Hematol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1038\/leu.2017.126","article-title":"Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations","volume":"31","author":"Zhang","year":"2017","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood-2013-05-500959","article-title":"The new genetics of chronic neutrophilic leukemia and atypical CML: Implications for diagnosis and treatment","volume":"122","author":"Gotlib","year":"2013","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: An international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1309\/AJCP3Z2AKUWRGTNM","article-title":"Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations","volume":"133","author":"Lakey","year":"2010","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"12367","DOI":"10.2147\/OTT.S287944","article-title":"Impact of Mutational Profile on the Management of Myeloproliferative Neoplasms: A Short Review of the Emerging Data","volume":"13","author":"Loscocco","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","article-title":"Targeted deep sequencing in polycythemia vera and essential thrombocythemia","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management","volume":"96","author":"Tefferi","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: Molecular pathophysiology, essential clinical understanding, and treatment strategies","volume":"29","author":"Tefferi","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/s41375-018-0078-0","article-title":"U2AF1 mutation types in primary myelofibrosis: Phenotypic and prognostic distinctions","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/leu.2014.57","article-title":"CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: An international study of 570 patients","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood-2014-05-579136","article-title":"Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1038\/leu.2014.148","article-title":"Calreticulin mutations and long-term survival in essential thrombocythemia","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2016.75","article-title":"Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified","volume":"29","author":"Wang","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1182\/blood.2019004229","article-title":"Molecular landscape and clonal architecture of adult myelodysplastic\/myeloproliferative neoplasms","volume":"136","author":"Palomo","year":"2020","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2013.122","article-title":"CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.3324\/haematol.2013.085050","article-title":"Prevalence of a new auto-activating colony stimulating factor 3 receptor mutation (CSF3R-T595I) in acute myeloid leukemia and severe congenital neutropenia","volume":"98","author":"Beekman","year":"2013","journal-title":"Haematologica"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1182\/blood-2016-04-709899","article-title":"CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML","volume":"127","author":"Maxson","year":"2016","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/bjh.13439","article-title":"CSF3R and CALR mutations in paediatric myeloid disorders and the association of CSF3R mutations with translocations, including t(8; 21)","volume":"170","author":"Sano","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1038\/leu.2013.182","article-title":"Mutation of the colony-stimulating factor-3 receptor gene is a rare event with poor prognosis in chronic myelomonocytic leukemia","volume":"27","author":"Kosmider","year":"2013","journal-title":"Leukemia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i (17) (q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/blood-2016-10-695981","article-title":"Genomics of chronic neutrophilic leukemia","volume":"129","author":"Maxson","year":"2017","journal-title":"Blood"},{"key":"ref_56","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). Polycythaemia vera. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, revised, IARC Press. [4th ed.]."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Gruppo Italiano Studio Policitemia (1995). Polycythemia vera: The natural history of 1213 patients followed for 20 years. Ann. Intern. Med., 123, 656\u2013664.","DOI":"10.7326\/0003-4819-123-9-199511010-00003"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ajh.23694","article-title":"Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients","volume":"89","author":"Barbui","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1309\/6BQ5K8LHVYAKUAF4","article-title":"The significance of bone marrow biopsy and JAK2V617F mutation in the differential diagnosis between the \u201cearly\u201d prepolycythemic phase of polycythemia vera and essential thrombocythemia","volume":"130","author":"Gianelli","year":"2008","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000084673","article-title":"Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia","volume":"113","author":"Thiele","year":"2005","journal-title":"Acta Haematol."},{"key":"ref_62","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). Primary myelofibrosis. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, revised, IARC Press. [4th ed.]."},{"key":"ref_63","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). Essential thrombocythaemia. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, revised, IARC Press. [4th ed.]."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1182\/blood-2014-06-583161","article-title":"Presence of calreticulin mutations in JAK2-negative polycythemia vera","volume":"124","author":"Broseus","year":"2014","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/S0950-3536(98)80036-X","article-title":"The histopathology of chronic myeloproliferative diseases","volume":"11","author":"Georgii","year":"1998","journal-title":"Bailli\u00e8re\u2019s Clin. Haematol."},{"key":"ref_66","first-page":"317","article-title":"Diagnostic impact of bone marrow histopathology in polycythemia vera (PV)","volume":"20","author":"Thiele","year":"2005","journal-title":"Histol. Histopathol."},{"key":"ref_67","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"ref_68","first-page":"144","article-title":"Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies","volume":"23","author":"Ellis","year":"1986","journal-title":"Semin. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1053\/j.seminhematol.2005.05.020","article-title":"Bone marrow histopathology in myeloproliferative disorders\u2014current diagnostic approach","volume":"42","author":"Thiele","year":"2005","journal-title":"Semin. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1002\/ajh.21543","article-title":"Prodromal myeloproliferative neoplasms: The 2008 WHO classification","volume":"85","author":"Kvasnicka","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/j.1600-0609.2010.01548.x","article-title":"The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera","volume":"86","author":"Abdulkarim","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1182\/blood-2011-11-393819","article-title":"Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome","volume":"119","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0344-0338(11)80081-6","article-title":"Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification","volume":"189","author":"Buhr","year":"1993","journal-title":"Pathol. Res. Pract."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000083452","article-title":"The incidence of myelofibrosis in essential thrombocythaemia, polycythaemia vera and chronic idiopathic myelofibrosis: A retrospective evaluation of sequential bone marrow biopsies","volume":"113","author":"Kreft","year":"2005","journal-title":"Acta Haematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.beha.2005.07.015","article-title":"Bone marrow histopathology in the diagnosis of chronic myeloproliferative disorders: A forgotten pearl","volume":"19","author":"Thiele","year":"2006","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11899-009-0005-6","article-title":"The 2008 WHO diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis","volume":"4","author":"Thiele","year":"2009","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: A literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1038\/modpathol.2013.109","article-title":"Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage","volume":"26","author":"Boiocchi","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/PAI.0000000000000000","article-title":"Myelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis","volume":"22","author":"Sangle","year":"2014","journal-title":"Appl. Immunohistochem. Mol. Morphol. AIMM\/Off. Publ. Soc. Appl. Immunohistochem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1038\/modpathol.2015.100","article-title":"Neutrophilic leukocytosis in advanced stage polycythemia vera: Hematopathologic features and prognostic implications","volume":"28","author":"Boiocchi","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/nrd4088","article-title":"Therapeutic modulators of STAT signalling for human diseases","volume":"12","author":"Miklossy","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.1002\/ajh.25017","article-title":"JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V > F mutation in patients with polycythemia vera or essential thrombocythemia","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e438","DOI":"10.3324\/haematol.2015.129510","article-title":"DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype","volume":"100","author":"Nangalia","year":"2015","journal-title":"Haematologica"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1038\/leu.2017.268","article-title":"Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis","volume":"31","author":"Tefferi","year":"2017","journal-title":"Leukemia"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1096\/fj.09-145482","article-title":"Calreticulin: Non-endoplasmic reticulum functions in physiology and disease","volume":"24","author":"Gold","year":"2010","journal-title":"FASEB J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/leu.2014.270","article-title":"Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: Relevance for disease evolution","volume":"29","author":"Cabagnols","year":"2015","journal-title":"Leukemia"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1038\/leu.2016.47","article-title":"Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin","volume":"30","author":"Balligand","year":"2016","journal-title":"Leukemia"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1182\/blood-2015-11-681932","article-title":"Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants","volume":"127","author":"Chachoua","year":"2016","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2159-8290.CD-15-1434","article-title":"Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation","volume":"6","author":"Elf","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/leu.2016.32","article-title":"Thrombopoietin receptor is required for the oncogenic function of CALR mutants","volume":"30","author":"Nivarthi","year":"2016","journal-title":"Leukemia"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ajh.24978","article-title":"Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1095 patients","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/blood.2019002561","article-title":"Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning","volume":"135","author":"Bridgford","year":"2020","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1038\/leu.2015.271","article-title":"Oncogenic activation of MPL\/thrombopoietin receptor by 17 mutations at W515: Implications for myeloproliferative neoplasms","volume":"30","author":"Defour","year":"2016","journal-title":"Leukemia"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Pikman, Y., Lee, B.H., Mercher, T., McDowell, E., Ebert, B.L., Gozo, M., Cuker, A., Wernig, G., Moore, S., and Galinsky, I. (2006). MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030270"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1182\/blood-2005-06-2600","article-title":"An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor","volume":"107","author":"Staerk","year":"2006","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","article-title":"Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms","volume":"127","author":"Nivarthi","year":"2016","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1056\/NEJM200004273421706","article-title":"Myelofibrosis with myeloid metaplasia","volume":"342","author":"Tefferi","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.1182\/blood-2010-07-293761","article-title":"Essential thrombocythemia versus early primary myelofibrosis: A multicenter study to validate the WHO classification","volume":"117","author":"Thiele","year":"2011","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1055\/s-2006-939433","article-title":"Clinicopathological criteria for differential diagnosis of thrombocythemias in various myeloproliferative disorders","volume":"32","author":"Thiele","year":"2006","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_107","first-page":"93","article-title":"Diagnostic differentiation of essential thrombocythaemia from thrombocythaemias associated with chronic idiopathic myelofibrosis by discriminate analysis of bone marrow features\u2014A clinicopathological study on 272 patients","volume":"18","author":"Thiele","year":"2003","journal-title":"Histol. Histopathol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.beha.2014.07.004","article-title":"Essential thrombocythemia vs. early\/prefibrotic myelofibrosis: Why does it matter","volume":"27","author":"Barosi","year":"2014","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000076524","article-title":"Prefibrotic chronic idiopathic myelofibrosis\u2014A diagnostic enigma?","volume":"111","author":"Thiele","year":"2004","journal-title":"Acta Haematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.seminoncol.2005.04.010","article-title":"Hematopathologic findings in chronic idiopathic myelofibrosis","volume":"32","author":"Thiele","year":"2005","journal-title":"Semin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/10428190500046554","article-title":"Bone marrow CD34+ progenitor cells in Philadelphia chromosome-negative chronic myeloproliferative disorders\u2014A clinicopathological study on 575 patients","volume":"46","author":"Thiele","year":"2005","journal-title":"Leuk. Lymphoma"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s11899-013-0186-x","article-title":"WHO classification of myeloproliferative neoplasms (MPN): A critical update","volume":"8","author":"Kvasnicka","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/his.12871","article-title":"Problems and pitfalls in grading of bone marrow fibrosis, collagen deposition and osteosclerosis\u2014A consensus-based study","volume":"68","author":"Kvasnicka","year":"2016","journal-title":"Histopathology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1053\/j.seminhematol.2005.05.018","article-title":"Idiopathic myelofibrosis","volume":"42","author":"Barosi","year":"2005","journal-title":"Semin. Hematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1365-2141.2007.06885.x","article-title":"Bone marrow microvessel density in chronic myeloproliferative disorders: A study of 115 patients with clinicopathological and molecular correlations","volume":"140","author":"Boveri","year":"2008","journal-title":"Br. J. Haematol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1309\/PTVGB3DXB8A8M7KD","article-title":"Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens","volume":"119","author":"Buhr","year":"2003","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_117","first-page":"1245","article-title":"Bone marrow angiogenesis: Methods of quantification and changes evolving in chronic myeloproliferative disorders","volume":"19","author":"Kvasnicka","year":"2004","journal-title":"Histol. Histopathol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00277-001-0417-4","article-title":"CD34+ progenitor cells in idiopathic (primary) myelofibrosis: A comparative quantification between spleen and bone marrow tissue","volume":"81","author":"Thiele","year":"2002","journal-title":"Ann. Hematol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1038\/modpathol.3800480","article-title":"Morphologic and immunohistochemical evaluation of splenic hematopoietic proliferations in neoplastic and benign disorders","volume":"18","author":"Kim","year":"2005","journal-title":"Mod. Pathol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1172\/JCI64397","article-title":"Spleens of myelofibrosis patients contain malignant hematopoietic stem cells","volume":"122","author":"Wang","year":"2012","journal-title":"J. Clin. Investig."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1038\/modpathol.2012.33","article-title":"Splenic extramedullary hematopoietic proliferation in Philadelphia chromosome-negative myeloproliferative neoplasms: Heterogeneous morphology and cytological composition","volume":"25","author":"Prakash","year":"2012","journal-title":"Mod. Pathol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF02915123","article-title":"Splenic haematopoiesis in primary (idiopathic) osteomyelofibrosis: Immunohistochemical and morphometric evaluation of proliferative activity of erytro- and endoreduplicative capacity of megakaryopoiesis (PCNA- and Ki-67 staining)","volume":"64","author":"Thiele","year":"1993","journal-title":"Virchows Arch. B Cell Pathol. Incl. Mol. Pathol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","article-title":"Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: An international study","volume":"29","author":"Barbui","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1053\/j.seminhematol.2005.05.022","article-title":"Essential thrombocythemia","volume":"42","author":"Finazzi","year":"2005","journal-title":"Semin. Hematol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0889-8588(03)00082-0","article-title":"Essential thrombocythemia. Essential thrombocythemia","volume":"17","author":"Harrison","year":"2003","journal-title":"Hematol.\/ Oncol. Clin."},{"key":"ref_126","first-page":"911","article-title":"Value of bone marrow biopsy in the diagnosis of essential thrombocythemia","volume":"89","author":"Florena","year":"2004","journal-title":"Haematologica"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1080\/10428190600678975","article-title":"Essential thrombocythemia or chronic idiopathic myelofibrosis? A single-center study based on hematopoietic bone marrow histology","volume":"47","author":"Gianelli","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00277-002-0604-y","article-title":"Chronic myeloproliferative disorders with thrombocythemia: A comparative study of two classification systems (PVSG, WHO) on 839 patients","volume":"82","author":"Thiele","year":"2003","journal-title":"Ann. Hematol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/ajh.10116","article-title":"Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): A retrospective clinicopathological study of 120 patients","volume":"70","author":"Thiele","year":"2002","journal-title":"Am. J. Hematol."},{"key":"ref_130","first-page":"1126","article-title":"Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis","volume":"85","author":"Thiele","year":"2000","journal-title":"Haematologica"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: A collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"ref_134","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). Chronic eosinophilic leukaemia, NOS. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, revised, IARC Press. [4th ed.]."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/ajh.23193","article-title":"Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation","volume":"87","author":"Helbig","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_138","unstructured":"Silverberg, S.G., DeLellis, R.A., and Sobin, L.H. (2016). Chronic eosinophilic leukemia, NOS and hypereosinophilic syndrome. Tumors of the Bone Marrow, 4th series ed., ARP Press."},{"key":"ref_139","first-page":"2","article-title":"Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome","volume":"95","author":"Bain","year":"1996","journal-title":"Br. J. Haematol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/j.1365-2141.1986.tb04089.x","article-title":"Chromosome and cell culture studies in eosinophilic leukaemia","volume":"62","author":"Parreira","year":"1986","journal-title":"Br. J. Haematol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/leu.2016.73","article-title":"Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing","volume":"30","author":"Pardanani","year":"2016","journal-title":"Leukemia"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41375-018-0342-3","article-title":"Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia","volume":"33","author":"Cross","year":"2019","journal-title":"Leukemia"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/bjh.12963","article-title":"Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?","volume":"166","author":"Bain","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3324\/haematol.2016.144345","article-title":"Characterization of leukemias with ETV6-ABL1 fusion","volume":"101","author":"Zaliova","year":"2016","journal-title":"Haematologica"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40364-016-0070-7","article-title":"A novel three-way rearrangement involving ETV6 (12p13) and ABL1 (9q34) with an unknown partner on 3p25 resulting in a possible ETV6-ABL1 fusion in a patient with acute myeloid leukemia: A case report and a review of the literature","volume":"4","author":"Tirado","year":"2016","journal-title":"Biomark. Res."},{"key":"ref_146","unstructured":"Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., and Thiele, J. (2017). Myeloproliferative neoplasm, unclassifiable. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues, revised, IARC Press. [4th ed.]."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2017.2","article-title":"The myeloproliferative neoplasms, unclassifiable: Clinical and pathological considerations","volume":"30","author":"Gianelli","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1309\/AJCPALP51XDIXDDV","article-title":"The Prevalence of JAK2, MPL, and CALR Mutations in Chinese Patients With BCR-ABL1-Negative Myeloproliferative Neoplasms","volume":"144","author":"Lin","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001\u20132012","volume":"174","author":"Srour","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/leu.2015.360","article-title":"Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: Comparison between the BCSH and the WHO criteria","volume":"30","author":"Gisslinger","year":"2016","journal-title":"Leukemia"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"E48","DOI":"10.1002\/ajh.24657","article-title":"Impact of the 2016 revised WHO criteria for myeloproliferative neoplasms, unclassifiable: Comparison with the 2008 version","volume":"92","author":"Iurlo","year":"2017","journal-title":"Am. J. Hematol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","article-title":"Bone marrow pathology in essential thrombocythemia: Interobserver reliability and utility for identifying disease subtypes","volume":"111","author":"Wilkins","year":"2008","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-020-0290-9","article-title":"The new WHO classification for essential thrombocythemia calls for revision of available evidences","volume":"10","author":"Barbui","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1002\/ajh.24338","article-title":"Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia","volume":"91","author":"Elala","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1182\/bloodadvances.2020002230","article-title":"Artificial intelligence-based morphological fingerprinting of megakaryocytes: A new tool for assessing disease in MPN patients","volume":"4","author":"Sirinukunwattana","year":"2020","journal-title":"Blood Adv."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/modpathol.2017.182","article-title":"Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: A multi-institutional study from the bone marrow pathology group","volume":"31","author":"Soderquist","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1093\/ajcp\/aqz069","article-title":"Genetic Testing in the Diagnosis and Biology of Myeloid Neoplasms (Excluding Acute Leukemias)","volume":"152","author":"Hasserjian","year":"2019","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1182\/blood-2014-12-616847","article-title":"CALR-mutated essential thrombocythemia evolving to chronic myeloid leukemia with coexistent CALR mutation and BCR-ABL translocation","volume":"125","author":"Bonzheim","year":"2015","journal-title":"Blood"},{"key":"ref_161","first-page":"e21","article-title":"Co-occurrence of BCR-ABL1-positive chronic myeloid leukaemia and CALR-mutated essential thrombocythaemia","volume":"188","author":"Traina","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"e18811","DOI":"10.1097\/MD.0000000000018811","article-title":"Atypical myeloproliferative neoplasm with concurrent BCR-ABL1 fusion and CALR mutation: A case report and literature review","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/ajcp\/aqw033","article-title":"Pure Erythroid Leukemia and Erythroblastic Sarcoma Evolving From Chronic Myeloid Neoplasms","volume":"145","author":"Li","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/modpathol.2012.165","article-title":"Development of monocytosis in patients with primary myelofibrosis indicates an accelerated phase of the disease","volume":"26","author":"Boiocchi","year":"2013","journal-title":"Mod. Pathol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1016\/j.humpath.2014.08.014","article-title":"The detection of SRSF2 mutations in routinely processed bone marrow biopsies is useful in the diagnosis of chronic myelomonocytic leukemia","volume":"45","author":"Federmann","year":"2014","journal-title":"Hum. Pathol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/14\/3528\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:30:24Z","timestamp":1760164224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/14\/3528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":165,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2021,7]]}},"alternative-id":["cancers13143528"],"URL":"https:\/\/doi.org\/10.3390\/cancers13143528","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]}}}